AstraZeneca Aktie

78,71USD 0,66USD 0,85%
AstraZeneca für 0 Euro bei ZERO ordern (zzgl. Spreads)
WKN: 886715 / ISIN: US0463531089
<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>

Aktionärsstruktur

Inhaber in %
Freefloat 99,98
Wellington Management Co. LLP (Wellington Breakout) 1,52
PRIMECAP Management Co. 1,39
T Rowe Price Associates, Inc. (13F Subfiler) 1,31
Capital Research & Management Co. (International Investors) 1,11
Vanguard PRIMECAP Fund 0,83
Washington Mutual Investors Fund 0,76
T. Rowe Price International Ltd. 0,66
Jennison Associates LLC 0,56
Vanguard Wellington Fund 0,54

*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.

Personal

2019 2020 2021 2022 2023
Personal am Ende des Jahres 70 600 76 100 83 100 83 500 89 900
Umsatz pro Mitarbeiter in Mio. EUR 0,35 0,36 0,46 0,53 0,51

Bilanz (in Mio. EUR) - Aktiva

2019 2020 2021 2022 2023
Summe Umlaufvermögen 15 563 19 544 26 244 22 593 25 054
Summe Anlagevermögen 31 354 36 002 70 049 66 269 67 765
Summe Aktiva 61 377 66 729 105 363 96 483 101 119

Bilanz (in Mio. EUR) - Passiva

2019 2020 2021 2022 2023
Gesamtverschuldung/ -verbindlichkeiten 18 227 20 380 30 781 29 232 28 622
Summe Fremdkapital 46 781 51 091 66 076 59 425 61 953
Summe Eigenkapital 14 596 15 638 39 287 37 058 39 166
Summe Passiva 61 377 66 729 105 363 96 483 101 119

Adresse

Cambridge Biomedical Campus, CB2 0AA Cambridge
Telefon +44 (20) 3749-5000
Internet http://www.astrazeneca.co.uk

Management

Adrian Charles Noel Kemp
Secretary
Alberto Hegewisch
Chief Medical Officer
Andreas Rummelt
Non-Executive Director
Anna Olive Magdelene Manz
Non-Executive Director
Aradhana Sarin
Chief Financial Officer & Executive Director
Cindy L. Hoots
Chief Digital & Information Officer
David Fredrickson
Executive Vice President-Oncology Business Unit
Deborah DiSanzo
Independent Non-Executive Director
Diana Layfield
Non-Executive Director
Euan A. Ashley
Non-Executive Director
Helen MacPhee
Vice President
Iskra Reic
EVP-Vaccines & Immune Therapies
Jeffrey Pott
CHRO, Chief Compliance Officer & General Counsel
Jonathan Thomas Charles Slade
Group Treasurer
Kevin G. Lokay
Head-Change Implementation
Marc Pierre Jean Dunoyer
Chief Strategy Officer
Marcus Wallenberg
Independent Non-Executive Director
Margareta Elisabeth Björk
Senior VP & Head-Late-stage Development
Michel Demaré
Chairman
Nazneen Rahman
Independent Non-Executive Director
Pam P. Cheng
Executive VP-Operations & Information Technology
Pascal Soriot
Chief Executive Officer & Executive Director
Philip Arthur John Broadley
Senior Independent Non-Executive Director
Regina Fritsche Danielson
SVP, Head-Research & Early Development
Ruud Dobber
Executive VP-Biopharmaceuticals Business
Sharon Barr
EVP-BioPharmaceuticals Research & Development
Sherilyn D. McCoy
Independent Non-Executive Director
Shu Kam Mok
Independent Non-Executive Director
Sjoerd Hubben
Vice President-Global Government Affairs & Policy
Susan Mary Galbraith
Executive VP-Oncology Research & Development
Tyrell J. Rivers
Executive Director-Corporate Development